-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

Benzinga·03/20/2026 14:36:35
Listen to the news
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $60 to $62.